Trial ID 20249 | Maryland Oncology Hematology Trial ID 20249 – Maryland Oncology Hematology

Trial ID 20249

Trial Information - Phase III

A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cance

Disease Specifics: NSCLC

Protocol ID: 61186372NSC3001

Sponsor: JANSSEN

Status: STAR Trial

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Lung

Status

STAR Trial

Sponsor

JANSSEN

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology